BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng S, Eyler SJ, Zhang Y, Maga T, Nester CM, Kroll MH, Smith RJ, Afshar-Kharghan V. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122:1487-1493. [PMID: 23847193 DOI: 10.1182/blood-2013-03-492421] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Furmańczyk-Zawiska A, Kubiak-Dydo A, Użarowska-Gąska E, Kotlarek-Łysakowska M, Salata K, Kolanowska M, Świerniak M, Gaj P, Leszczyńska B, Daniel M, Jażdżewski K, Durlik M, Wójcicka A. Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)-A Series of Cases from a Single Family. J Pers Med 2021;11:304. [PMID: 33920896 DOI: 10.3390/jpm11040304] [Reference Citation Analysis]
2 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol 2020;27:341-52. [PMID: 32701617 DOI: 10.1097/MOH.0000000000000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Nalluru SS, Sridharan M, Go RS, Said S, Marshall AL. Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy. Am J Med Sci 2018;356:492-8. [PMID: 30177262 DOI: 10.1016/j.amjms.2018.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
6 Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017;3. [DOI: 10.1038/nrdp.2017.20] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 21.0] [Reference Citation Analysis]
7 Noone DG, Riedl M, Pluthero FG, Bowman ML, Liszewski MK, Lu L, Quan Y, Balgobin S, Schneppenheim R, Schneppenheim S, Budde U, James P, Atkinson JP, Palaniyar N, Kahr WH, Licht C. Von Willebrand factor regulates complement on endothelial cells. Kidney Int 2016;90:123-34. [PMID: 27236750 DOI: 10.1016/j.kint.2016.03.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
8 Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol 2018;22:653-60. [PMID: 28939980 DOI: 10.1007/s10157-017-1478-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J 2019;17:10. [PMID: 31160889 DOI: 10.1186/s12959-019-0198-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 19.3] [Reference Citation Analysis]
10 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
11 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, Coucelo M, Manco L, Maia T, Mendes MJ, Del Orbe Barreto R, Corrales I, Vidal F, Ribeiro ML. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost 2017;1:69-80. [PMID: 30046676 DOI: 10.1002/rth2.12016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
13 Sasapu A, Cottler-Fox M, Motwani P. Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. Proc (Bayl Univ Med Cent) 2017;30:182-3. [PMID: 28405075 DOI: 10.1080/08998280.2017.11929576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
14 Rosove MH. Thrombotic microangiopathies. Seminars in Arthritis and Rheumatism 2014;43:797-805. [DOI: 10.1016/j.semarthrit.2013.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
15 Vardas PN, Hashmi ZA, Hadi MA. Identification and management of atypical hemolytic uremic syndrome immediately post-heart transplantation. J Card Surg 2015;30:373-5. [PMID: 25693626 DOI: 10.1111/jocs.12520] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Arons E, Adams S, Venzon DJ, Pastan I, Kreitman RJ. Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. Br J Haematol 2014;166:729-38. [PMID: 24931452 DOI: 10.1111/bjh.12956] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
17 Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol. 2014;25:2053-2065. [PMID: 24652797 DOI: 10.1681/asn.2013070796] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
18 Novikov P, Kozlovskaya N, Moiseev S, Shilov E, Bobkova I, Schreiber A, Tsvetkov D, Gollasch M, Mah N, El Amrani K, Kurtz A. Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy. Biomed Hub 2016;1:1-11. [PMID: 31988889 DOI: 10.1159/000453106] [Reference Citation Analysis]
19 Kok VC, Wu SC, Lee CK. Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer. Breast Cancer (Auckl) 2014;8:57-9. [PMID: 24701120 DOI: 10.4137/BCBCR.S14920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125:3637-46. [PMID: 25862562 DOI: 10.1182/blood-2015-02-629683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
21 Podd BS, Simon DW, Lopez S, Nowalk A, Aneja R, Carcillo JA. Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure. Pediatr Clin North Am 2017;64:1071-88. [PMID: 28941536 DOI: 10.1016/j.pcl.2017.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
22 Hong H, Xiao W, Stempak LM, Sandhaus LM, Maitta RW. Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura. Transfusion 2015;55:756-65. [PMID: 25370931 DOI: 10.1111/trf.12912] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
23 Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatr Nephrol 2018;33:1297-307. [DOI: 10.1007/s00467-017-3744-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost 2018;16:618-29. [DOI: 10.1111/jth.13956] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
25 Chang JC. TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease. Thromb J 2018;16:20. [PMID: 30127669 DOI: 10.1186/s12959-018-0174-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
26 Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, Van Praet J, Pani A, De Vriese AS. Diagnosis of complement alternative pathway disorders. Kidney International 2016;89:278-88. [DOI: 10.1016/j.kint.2015.12.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
27 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
28 Chauvet S, Berthaud R, Devriese M, Mignotet M, Vieira Martins P, Robe-Rybkine T, Miteva MA, Gyulkhandanyan A, Ryckewaert A, Louillet F, Merieau E, Mestrallet G, Rousset-Rouvière C, Thervet E, Hogan J, Ulinski T, Villoutreix BO, Roumenina L, Boyer O, Frémeaux-Bacchi V. Anti-Factor B Antibodies and Acute Postinfectious GN in Children. J Am Soc Nephrol 2020;31:829-40. [PMID: 32034108 DOI: 10.1681/ASN.2019080851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
29 Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes.Hematol Oncol Clin North Am. 2015;29:509-524. [PMID: 26043389 DOI: 10.1016/j.hoc.2015.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
30 Goel A, Raghupathy V, Amirtharaj GJ, Chapla A, Venkatraman A, Ramakrishna B, Ramachandran A, Thomas N, Balasubramanian KA, Mackie I, Elias E, Eapen CE. ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension. Indian J Gastroenterol 2017;36:380-9. [DOI: 10.1007/s12664-017-0786-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Cidon EU, Martinez PA, Hickish T. Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature. World J Clin Cases 2018; 6(12): 531-537 [PMID: 30397609 DOI: 10.12998/wjcc.v6.i12.531] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
33 Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 2017;130:368-72. [PMID: 28461395 DOI: 10.1182/blood-2017-02-770214] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
34 Nester CM, Smith RJ. Factors influencing treatment of atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2014;9:1516-8. [PMID: 25135763 DOI: 10.2215/CJN.07540714] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Schrezenmeier E, Kremerskothen E, Halleck F, Staeck O, Liefeldt L, Choi M, Schüler M, Weber U, Bachmann N, Grohmann M, Wagner T, Budde K, Bergmann C. The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. Genet Med 2021;23:1219-24. [PMID: 33712733 DOI: 10.1038/s41436-021-01127-8] [Reference Citation Analysis]
36 Fidan K, Göknar N, Gülhan B, Melek E, Yıldırım ZY, Baskın E, Hayran M, Gülleroglu K, Özçakar ZB, Ozaltin F, Soylemezoglu O. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2018;33:1395-403. [PMID: 29610995 DOI: 10.1007/s00467-018-3933-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
37 Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, Lane A, Meller J, Medvedovic M, Chen J, Davies SM. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016;127:989-96. [PMID: 26603840 DOI: 10.1182/blood-2015-08-663435] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 13.6] [Reference Citation Analysis]
38 Feng S, Liang X, Kroll MH, Chung DW, Afshar-Kharghan V. von Willebrand factor is a cofactor in complement regulation. Blood 2015;125:1034-7. [PMID: 25395424 DOI: 10.1182/blood-2014-06-585430] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
39 Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015;13 Suppl 1:S121-32. [PMID: 26149013 DOI: 10.1111/jth.12950] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 10.0] [Reference Citation Analysis]
40 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
41 Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:307-15. [PMID: 26456258 DOI: 10.1016/j.bbmt.2015.10.002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 11.7] [Reference Citation Analysis]
42 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
43 Magro CM, Momtahen S, Mulvey JJ, Yassin AH, Kaplan RB, Laurence JC. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol 2015;37:349-56; quiz 357-9. [PMID: 25893747 DOI: 10.1097/DAD.0000000000000234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
44 Yüksel S, Işık Gönül İ, Canpolat N, Gökçe İ, Özlü SG, Özçakar ZB, Ozaltin F, Söylemezoğlu O. Renal Biopsy Prognostic Findings in Children With Atypical Hemolytic Uremic Syndrome. Pediatr Dev Pathol 2020;23:362-71. [PMID: 32406813 DOI: 10.1177/1093526620925947] [Reference Citation Analysis]
45 Vincent JL, Castro P, Hunt BJ, Jörres A, Praga M, Rojas-Suarez J, Watanabe E. Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies-what intensivists need to know. Crit Care 2018;22:158. [PMID: 29895296 DOI: 10.1186/s13054-018-2073-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
46 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
47 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]